1. FDA aprueba nuevo fármaco contra la esclerosis múltiple  Nación Farma
  2. Estados Unidos aprueba Mayzent, de Novartis, en esclerosis múltiple  Redacción Médica
  3. Ver cobertura completa en Google Noticias
La ha aprobado Mayzent (siponimod) para tratar a adultos con formas recurrentes de esclerosis múltipleLa eficacia y seguridad de este medicamento fue probada en 1.651

EEUU aprueba Mayzent (Novartis) en esclerosis múltiple

A study based on RRMS patients in two Phase 3 trials supports blood levels of neurofilament light chain (NfL) as an reliable biomarker of MS activity.A study based on RRMS patients in two Phase 3 trials supports blood levels of neurofilament light chain (NfL) as an reliable biomarker of MS activity.

MS Activity and Treatment Response Evident in Neurofilament Light Chain Levels in Blood, Study Says

A study, partly by Novartis researchers and based on a US health database, found benefits in MS patients using Gilenya continuously for up to three years.A study, partly by Novartis researchers and based on a US health database, found benefits in MS patients using Gilenya continuously for up to three years.

MS Patients Using Gilenya Long-term Show 50% Drop in Annual Relapse Rates, Real-world Study Says